Phytohealth Corp (4108) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phytohealth Corp (4108) has a cash flow conversion efficiency ratio of -0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.92 Million ≈ $-186.54K USD) by net assets (NT$2.29 Billion ≈ $72.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Phytohealth Corp balance sheet independence to measure how much of total assets are equity-financed.
Phytohealth Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Phytohealth Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Phytohealth Corp to evaluate the quality of earnings relative to operating cash generation.
Phytohealth Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phytohealth Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADVENICA AB
F:65R
|
0.098x |
|
Sab Zenzele Kabili Holdings
JSE:SZK
|
0.020x |
|
e-LITECOM CO. Ltd
KQ:041520
|
-0.006x |
|
Foshan Electrical and Lighting Co Ltd
SHE:200541
|
0.012x |
|
Great Elm Capital Corp
NASDAQ:GECC
|
0.219x |
|
Makarony Polskie S.A.
WAR:MAK
|
0.058x |
|
WINS Co. Ltd
KQ:136540
|
0.022x |
|
BARK, Inc.
NYSE:BARK
|
0.021x |
Annual Cash Flow Conversion Efficiency for Phytohealth Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Phytohealth Corp from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see 4108 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$2.29 Billion ≈ $72.26 Million |
NT$-39.72 Million ≈ $-1.25 Million |
-0.017x | +18.20% |
| 2024-12-31 | NT$2.37 Billion ≈ $74.62 Million |
NT$-50.13 Million ≈ $-1.58 Million |
-0.021x | +12.24% |
| 2023-12-31 | NT$2.27 Billion ≈ $71.54 Million |
NT$-54.77 Million ≈ $-1.73 Million |
-0.024x | +8.36% |
| 2022-12-31 | NT$2.28 Billion ≈ $71.75 Million |
NT$-59.95 Million ≈ $-1.89 Million |
-0.026x | +7.86% |
| 2021-12-31 | NT$2.39 Billion ≈ $75.25 Million |
NT$-68.24 Million ≈ $-2.15 Million |
-0.029x | +67.11% |
| 2020-12-31 | NT$1.70 Billion ≈ $53.63 Million |
NT$-147.87 Million ≈ $-4.66 Million |
-0.087x | -25.30% |
| 2019-12-31 | NT$1.75 Billion ≈ $55.19 Million |
NT$-121.45 Million ≈ $-3.83 Million |
-0.069x | +4.67% |
| 2018-12-31 | NT$1.94 Billion ≈ $61.27 Million |
NT$-141.44 Million ≈ $-4.46 Million |
-0.073x | +0.29% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.45 Million |
NT$-151.52 Million ≈ $-4.77 Million |
-0.073x | +77.69% |
| 2016-12-31 | NT$2.32 Billion ≈ $72.95 Million |
NT$-756.87 Million ≈ $-23.85 Million |
-0.327x | -472.14% |
| 2015-12-31 | NT$2.30 Billion ≈ $72.36 Million |
NT$-131.22 Million ≈ $-4.13 Million |
-0.057x | -304.42% |
| 2014-12-31 | NT$2.39 Billion ≈ $75.25 Million |
NT$-33.74 Million ≈ $-1.06 Million |
-0.014x | +68.58% |
| 2013-12-31 | NT$2.74 Billion ≈ $86.30 Million |
NT$-123.18 Million ≈ $-3.88 Million |
-0.045x | +23.87% |
| 2012-12-31 | NT$2.78 Billion ≈ $87.67 Million |
NT$-164.37 Million ≈ $-5.18 Million |
-0.059x | +46.05% |
| 2011-12-31 | NT$1.56 Billion ≈ $49.24 Million |
NT$-171.09 Million ≈ $-5.39 Million |
-0.109x | -3.32% |
| 2010-12-31 | NT$1.82 Billion ≈ $57.41 Million |
NT$-193.06 Million ≈ $-6.08 Million |
-0.106x | -98.88% |
| 2009-12-31 | NT$2.01 Billion ≈ $63.36 Million |
NT$-107.15 Million ≈ $-3.38 Million |
-0.053x | -181.31% |
| 2006-12-31 | NT$1.32 Billion ≈ $41.63 Million |
NT$86.57 Million ≈ $2.73 Million |
0.066x | +30.10% |
| 2005-12-31 | NT$1.19 Billion ≈ $37.44 Million |
NT$59.85 Million ≈ $1.89 Million |
0.050x | -- |
About Phytohealth Corp
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. … Read more